Oliceridine: Examining the clinical evidence, pharmacology, and contested mechanism of action of the first FDA-approved biased opioid agonist

By afschroeder • October 23, 2025

Prommer EE. Oliceridine: Examining the clinical evidence, pharmacology, and contested mechanism of action of the first FDA-approved biased opioid agonist. J Opioid Manag. 2025 Sep-Oct;21(5):377-387. doi: 10.5055/jom.0958. PMID: 41123260.

Tags: General Internal Medicine, Publications, Veterans Administration

Could School Function Be an Adolescent Health Vital Sign? Associations Between Gradebook Data and Substance Use Among Middle School Students

DiPentino R, Meza BPL, Jackson N, Dosanjh KK, Dudovitz RN, Wong MD. Could School Function Be an Adolescent Health Vital Sign? Associations Between Gradebook Data[...]

Safety and Efficacy of the Ahmed ClearPath versus Ahmed ClearPath Small Tube at Six Months: A Retrospective Comparative Cohort Study

Shi KSY, Dorairaj EA, Bhartiya S, Oyama K, Wang W, Thé RY, Moreno KB, Wang M, Towne C, Qozat IM, Banoub RG, Dorairaj SK. Safety[...]

“Interstitial lung disease with associated severe pulmonary hypertension is rarely idiopathic by clinical or pathologic measures”

Brownstein AJ, Shaikh F, Xiao GQ, Wilhalme H, Abtin F, Stefanko DP, Liang LL, Hong J, Rahaghi F, Shino M, Samuel Weigt S, Sayah D,[...]